Company intelligence / Profile preview

Aclaris Therapeutics

Wayne, Pennsylvania, United States

Ownership: Public · ACRS
Development stage: Other

Overview

Lead program (ATI-2138) reported positive Phase 2a results as of July 2025, achieving both primary and key secondary endpoints in the targeted immuno-inflammatory indication[2].

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeMonoclonal antibodyBispecific monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Aclaris Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aclaris Therapeutics.

Explore the full profile